Skip to content

EBIT at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$130.25M+12.2%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.7M+2.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$100.53M+16.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$907.23M+54.1%
Enterprise value$898.76M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Calculated from Sana Biotechnology’s reported figures.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's EBIT?
Sana Biotechnology (SANA) reported EBIT of -$48.61M in Q1 2026.
How has Sana Biotechnology's EBIT changed year-over-year?
Sana Biotechnology's EBIT increased by 4.0% year-over-year, from -$50.63M to -$48.61M.
What is the long-term trend for Sana Biotechnology's EBIT?
Over 4 years (2021 to 2025), Sana Biotechnology's EBIT has grown at a -8.5% compound annual growth rate (CAGR), from -$356.91M to -$250.32M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.